Navigation Links
Oncolytics Biotech Inc. Announces 2008 First Quarter Results
Date:4/30/2008

e potential to significantly enhance the efficacy of oncolytic virotherapy. About a third of those patients also showed increases in NK (natural killer) cells following therapy. The data support the development of interventions aimed at blunting the patient's immune response, although preclinical data also suggest that maintaining a baseline level is necessary to restrict systemic spread and toxicity of the virus.

Manufacturing and Process Development

In the first quarter of 2008, after completing the technology transfer of our 40-litre production process to our manufacturer in the U.S., we commenced production at the 40-litre scale under cGMP conditions for use in our clinical trials. Our process development activity continued to focus on scale up from 40-litre to 100-litre production runs.

Intellectual Property

During the first quarter of 2008, one U.S. and two Canadian patents were issued. At the end of the first quarter of 2008, we had been issued over 170 patents including 26 U.S. and eight Canadian patents as well as issuances in other jurisdictions. We also have over 180 patent applications filed in the U.S., Canada and other jurisdictions.

Financial Impact

We estimated at the beginning of 2008 that our average monthly cash usage would be approximately $1,660,000 for 2008. Our cash usage for the first quarter of 2008 was $2,991,234 from operating activities and $259,969 for the purchases of intellectual property and capital assets which is lower than our expected monthly average but is in line with our expectations for 2008. Our net loss for the first quarter of 2007 was $3,324,241.

Cash Resources

We exited the first quarter of 2008 with cash resources totaling $21,962,626 (see "Liquidity and Capital Resources").

Expected REOLYSIN(R) Development for the Remainder of 2008

We plan to continue to enroll patients in our clinical trials throughout 2008 and still expect to complete enrollment in
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)...  Having the right people at the table for ... growth and achieving clinical and operational goals. The 22 ... July 20-22, 2014, in San Diego ... healthcare experts discussing how partnerships have positively impacted their ... Chief Executive Officer of Cape Regional Medical Center located ...
(Date:7/23/2014)... La Jolla, CA (PRWEB) July 23, 2014 ... adipose stem cell therapy in the US aimed at ... today announced their newest clinical study for Parkinson’s disease. ... and efficacy of stem cell therapy are paramount when ... , This clinical study makes stem cell therapy accessible ...
(Date:7/23/2014)... July 23, 2014 DuPont Pioneer announced ... as vice president of Agricultural Biotechnology (ABT), effective July ... he served most recently as president, chief executive officer ... business leadership in the seed and crop protection industry ... Paul E. Schickler , president of DuPont Pioneer. “I ...
(Date:7/23/2014)... regulated information -- UCB today announced an ... with positive topline results from the latest Phase ... designed to evaluate the efficacy and safety of ... titration) compared to placebo, as adjunctive treatment in ... fully controlled despite treatment with one or two ...
Breaking Biology Technology:MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7
... Pharma AG today,announced that the US Food and ... (IND) application submitted by Nitec for the,initiation of ... results of a European Phase III trial (CAPRA-1;,Circadian ... dossier for marketing authorization in Europe. The FDA,s,acceptance ...
... and advantageous for the U.S. Army,s Chemical Materials Agency ... waste during regular chemical agent disposal operations, says a ... committee that wrote the report also determined that the ... the submission of data from previous trial burns -- ...
... Pacific Northwest National Laboratory,have discovered a way to ... creation of a portable biosensor that can address ... nerve agents, the need to quickly distinguish between ... , The sensor components resemble a pregnancy test ...
Cached Biology Technology:Nitec's IND Application for Clinical Development With Lodotra Accepted by the FDA 2Nitec's IND Application for Clinical Development With Lodotra Accepted by the FDA 3Report recommends off-site disposal of secondary waste 2Report recommends off-site disposal of secondary waste 3Report recommends off-site disposal of secondary waste 4Truly sick or simply scared? 2
(Date:7/23/2014)... Chrysomya megacephala is commonly found in dead ... the time of death, referred to as the post ... C. megacephala from Tamil Nadu is provided ... molecular characterization through generation of DNA barcoding. This study, ... access Biodiversity Data Journal . , Chrysomya ...
(Date:7/23/2014)... struggle to deal with ever-growing piles of electronic waste ... just how much there is and where it really ... Science & Technology , their study found that nearly ... into just seven developing countries with major potential ... Knut Breivik and colleagues note that the export from ...
(Date:7/23/2014)... sulfur-oxidizing bacterial group called SUP05 will play an increasingly ... world,s oceans as oxygen minimum zones expand, according to ... the National Academy of Sciences . , University of ... anoxic fjord, Canada,s Saanich Inlet, to chart how microbial ... "Our study paints a very detailed picture of how ...
Breaking Biology News(10 mins):Dead body feeding larvae useful in forensic investigations 2Research charts the ecological impact of microbial respiration in the oxygen-starved ocean 2
... Connie Hedegaard, the EU commissioner for Climate Action, ... new Nordic centre for Europe,s main climate innovation ... entrepreneurs, businesses, climate professionals, students and government officials ... European partnership to work on innovative solutions for ...
... and technology (S&T) eroded further during the last decade, ... their innovation capacities. According to a report released today ... body of the National Science Foundation (NSF) and an ... economies, taken together, now perform a larger share of ...
... D.C., February 6, 2014Dietary supplement users take these ... effort to develop a healthier lifestyle, according to ... , a peer-reviewed scientific publication. The review, "Health ... Nutrition Journal .2014, 13:14), co-authored by Council for ...
Cached Biology News:European Union launches Nordic climate innovation center 2European Union launches Nordic climate innovation center 3US lead in science and technology shrinking 2US lead in science and technology shrinking 3US lead in science and technology shrinking 4Scientific review points to supplement users engaging in a pattern of healthy habits 2